A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms without systematic methodology or primary human data.
PubMed 37890514 · doi:10.1055/a-2181-0813
What was done
This is a narrative review describing the biological functions of the poly (ADP-ribose) polymerase (PARP) superfamily, focusing on PARP-1 mechanisms in DNA repair, proinflammatory gene transcription, and cellular energy depletion, and summarizing the rationale for PARP-1 pharmacological inhibitors in cancer therapy.
What was found
The abstract presents no quantitative data or empirical study findings. It notes that PARP-1 is the most common isoform responsible for more than 90% of tasks among the 18 identified PARP superfamily members, utilizes NAD+ as a substrate, and that pharmacological reduction of PARP-1 can increase cytotoxicity toward cancer cells.
Why it matters
It outlines the mechanistic basis for targeting PARP-1 to disrupt DNA repair and cellular pathways in oncology drug development.
Limits
This is an unsystematic narrative overview without empirical testing, quantitative clinical data, or safety and efficacy metrics.
Cited by
- supports When PARP1 detects DNA damage, it consumes NAD+ to synthesize poly(ADP-ribose) polymers that assemble DNA repair enzymes at the damage site.